Andere Sprachen Bio-Path Holdings, Inc.

Aktien

A403XM

US09057N4097

BPTH

Realtime-Estimate Cboe BZX Andere Börsenplätze 19:10:49 08.05.2024			% 5 Tage	% 1. Jan.
2,79 ^USD	-7,00 %		+2,50 %	-69,45 %

18.04.	Bio-Path Holdings, Inc. gibt den erfolgreichen Abschluss der zweiten Kohorte mit höherer Dosis in der klinischen Phase 1/1B-Studie mit Bp1002 bei Patienten mit refraktärer/rückfälliger akuter myeloischer Leukämie (AML) bekannt	CI
15.04.	Bio-Path Holdings, Inc. erweitert globales Patentportfolio	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024	13:02
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	22.04.
Bio-Path Closes $1.2 Million Share Offering	19.04.
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-theMarket Under Nasdaq Rules	19.04.
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	18.04.
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients	18.04.
Bio-Path Holdings, Inc. Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients	18.04.
Bio-Path Holdings Expands Global Patent Portfolio	15.04.
Bio-Path Holdings, Inc. Expands Global Patent Portfolio	15.04.
North American Morning Briefing : Investors on Edge as High-Stakes Jobs Report Awaited	05.04.
Bio-Path Holdings Provides 2024 Clinical and Operational Update	02.04.
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23	27.03.
Bio Path : Failure to Satisfy Listing Rule - Form 8-K	13.03.
Bio-Path Holdings Reports Full Year 2023 Financial Results	08.03.
North American Morning Briefing : Stock Futures -2-	08.03.
Bio-Path Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07.03.
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024	04.03.
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024	01.03.
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split	21.02.
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory Relapsed Lymphoma and Refractory Relapsed Chronic Lymphocytic Leukemia Patients	11.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Bio-Path Holdings, Inc.

Aktien

A403XM

US09057N4097

BPTH

Andere Sprachen

Filter